Identification of two theranostic biomarker panels for epithelial ovarian cancer

Habel, Azza; Xu, Weili; Ahmed, Mariem Hadj; Stayoussef, Mouna; Bouaziz, Hanen; Ayadi, Mouna; Mezlini, Amel; Larbi, Anis; Yaacoubi-Loueslati, Basma

doi:10.1016/j.cyto.2022.156051

Cited by 7 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, the high TNF‐α expression can inhibit the immune function and then increase the risk of further injury 27 . Studies have shown that the TNF‐α level is abnormally high in patients with ovarian cancer 22,28 . Here we found that recurrent patients have higher serum TNF‐α level than nonrecurrent patients.…”

Section: Discussionsupporting

confidence: 52%

“…27 Studies have shown that the TNF-α level is abnormally high in patients with ovarian cancer. 22,28 Here we found that recurrent patients have higher serum TNF-α level than nonrecurrent patients. Logistic regression equation analysis suggests that serum TNF-α is the influencing factors for patient recurrence, and the ROC curve shows that serum TNF-α levels have a certain diagnostic effect (AUC = 0.802) on ovarian cancer recurrence.…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

The role of inflammatory factors and T‐cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them

Maowulieti,

Zhao,

Zhao

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundThe aim of the study is to investigate the role of serum inflammatory factors and T‐cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparib on inflammatory factor and T‐lymphocyte subsets in patients with recurrent epithelial ovarian cancer.MethodsIn this study, 100 patients diagnosed as recurrent epithelial ovarian cancer in our hospital and 100 patients without recurrent epithelial ovarian cancer in the same period were selected. According to the treatment plan, the recurrent patients were divided into conventional therapy group (Paclitaxel and Carboplatin) and combined therapy group (Paclitaxel, Carboplatin, and olaparib). The levels of serum inflammatory factors were evaluated by enzyme‐linked immunosorbent assay. The peripheral blood T‐lymphocyte subsets in each group were detected by flow cytometry.ResultsCompared with nonrecurrent patients, recurrent patients have higher serum interleukin‐6 (IL‐6) and tumor necrosis factor‐α (TNF‐α) levels (p < .05), and lower interferon‐γ (IFN‐γ) level and the CD4+/CD8+ ratio. After adjusting for confounding factors, the results showed that the serum IL‐6, IFN‐γ, and TNF‐α levels were influencing factors of recurrence in epithelial ovarian cancer patients. The area under the receiver operating curve and the sensitivity of serum TNF‐α in predicting ovarian cancer recurrence were higher than those of IL‐6 and IFN‐γ. After secondary chemotherapy and/or olaparib maintenance treatment, the IL‐6 (p < .001) and TNF‐α (p < .001) levels in combined therapy group were lower than those in the conventional therapy, whereas the IFN‐γ level (p < .001), the CD4+ T‐cell proportion (p = .0069) and the CD4+/CD8+ ratio (p = .0201) were higher than those in the conventional therapy.ConclusionThe serum IL‐6, TNF‐α, and IFN‐γ levels were closely related to the recurrence of ovarian cancer. Olaparib maintenance treatment can significantly decrease the IL‐6 and TNF‐α level, and increase IFN‐γ level and the CD4+/CD8+ ratio in patients with recurrent ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 65%

The role of inflammatory factors and T‐cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them

Maowulieti,

Zhao,

Zhao

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…miR-21 and miR-125b are considered as biomarkers in ovarian cancer with overexpression. Moreover, downregulation of miR-125b causes platinum resistance in ovarian cancer (61). miR-1299 is another factor inhibiting cervical tumor.…”

Section: Mirna Biogenesis and Interaction With Molecular Pathwaysmentioning

confidence: 99%

Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis

Tian,

Zhang,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related deaths in the world. The development and progression of HCC are closely correlated with the abnormal regulation of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). Important biological pathways in cancer biology, such as cell proliferation, death, and metastasis, are impacted by these ncRNAs, which modulate gene expression. The abnormal expression of non-coding RNAs in HCC raises the possibility that they could be applied as new biomarkers for diagnosis, prognosis, and treatment targets. Furthermore, by controlling the expression of cancer-related genes, miRNAs can function as either tumor suppressors or oncogenes. On the other hand, lncRNAs play a role in the advancement of cancer by interacting with other molecules within the cell, which, in turn, affects processes such as chromatin remodeling, transcription, and post-transcriptional processes. The importance of ncRNA-driven regulatory systems in HCC is being highlighted by current research, which sheds light on tumor behavior and therapy response. This research highlights the great potential of ncRNAs to improve patient outcomes in this difficult disease landscape by augmenting the present methods of HCC care through the use of precision medicine approaches.

show abstract

“…The accurate identification of EOC patients is critical for therapeutic interventions . However, there is currently no noninvasive method available to accurately detect early stage EOC. , As tumor biomarkers, carbohydrate antigen 125 (CA125) and human epididymis 4 (HE4) have limited diagnostic utility . The accuracy of CA125 in the diagnosis of OC is affected by the age of patients .…”

mentioning

confidence: 99%

Identifying Serum Small Extracellular Vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer

Li,

Zhang,

Zhang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

There remains a lack of effective and noninvasive methods for the diagnosis and prognosis prediction of epithelial ovarian carcinoma (EOC). Here, we investigated the possibility of serum-derived small extracellular vesicle (sEV) microRNAs (miRNAs) as potential biomarkers for distinguishing between benign and malignant adnexal masses and predicting the prognosis of EOC patients. A serum sEV miRNA model for identifying the EOC (sEVmiR-EOC) was successfully established in the training cohort. Furthermore, the sEVmiR-EOC model was confirmed in the testing cohort and validation cohort, demonstrating robust diagnostic accuracy. The sEVmiR-EOC model showed better performance than carbohydrate antigen 125 (CA125) in discriminating patients with stage I EOC from benign patients. Using EOC samples and follow-up data, we identified miR-141-3p and miR-200c-3p as potential prognostic predictors. Finally, we confirmed the change of the sEVmiR-EOC RiskScore between the preoperative and postoperative samples and found that the sEVmiR-EOC model could predict the prognosis of EOC patients.

show abstract

Identification of two theranostic biomarker panels for epithelial ovarian cancer

Cited by 7 publications

References 36 publications

The role of inflammatory factors and T‐cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them

The role of inflammatory factors and T‐cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them

Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis

Identifying Serum Small Extracellular Vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer

Contact Info

Product

Resources

About